Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. SMMT
stocks logo

SMMT

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.093
+4.09%
--
--
-0.102
+27.3%
--
--
-0.122
+52.38%
Estimates Revision
The market is revising No Change the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.39%.
EPS Estimates for FY2025
Revise Downward
down Image
-3.44%
In Past 3 Month
Stock Price
Go Down
down Image
-1.39%
In Past 3 Month
11 Analyst Rating
up Image0
Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 33.50 USD with a low forecast of 12.00 USD and a high forecast of 44.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
1 Sell
Strong Buy
up Image0
Current: 19.850
sliders
Low
12.00
Averages
33.50
High
44.00
up Image0
Current: 19.850
sliders
Low
12.00
Averages
33.50
High
44.00
Leerink
Underperform
initiated
$12
2025-06-11
Reason
Leerink
Price Target
$12
2025-06-11
initiated
Underperform
Reason
Leerink initiated coverage of Summit Therapeutics with an Underperform rating and $12 price target. Ivonescimab, Summit Therapeutics' VEGF-A/PD-1 bispecific, is a strong product and Summit leadership deserves credit for licensing ex-China rights to the bispecific from Akeso long before the clinical outcomes were clearly compelling, the firm says. However, Leerink does not believe Ivonescimab is the next Keytruda. For the firm, consensus estimates assume an unrealistic share of the current anti-PD(L)1 total addressable market, given the intense and heterogenous competitive landscape, and compared to the PD-(L)1 era, higher threshold for clinical success, regulatory approval, and uptake.
Clear Street
Bill Maughan
initiated
$33
2025-05-22
Reason
Clear Street
Bill Maughan
Price Target
$33
2025-05-22
initiated
Reason
Clear Street analyst Bill Maughan last night initiated coverage of Summit Therapeutics with a Buy rating and $33 price target. Summit is a biotechnology company developing a single asset, ivonescimab, which is "the most exciting pipeline molecule in oncology today," the analyst tells investors in a research note. The firm says ivonescimab has already shown in multiple Phase 3 clinical studies that it can outperform standard-of-care immunotherapy, including the "best-selling global medicine" Keytruda in non-small cell lung cancer.
Clear Street
initiated
$33
2025-05-21
Reason
Clear Street
Price Target
$33
2025-05-21
initiated
Reason
Clear Street initiated coverage of Summit Therapeutics with a Buy rating and $33 price target.
TD Cowen
Tyler Van Buren
Buy
initiated
2025-05-08
Reason
TD Cowen
Tyler Van Buren
Price Target
2025-05-08
initiated
Buy
Reason
TD Cowen analyst Tyler Van Buren initiated coverage of Summit Therapeutics with a Buy rating and no price target. The firm says ivonescimab's "exquisite engagement" of PD-1 and VEGF has translated to superiority versus chemo in second-line EGFRm lung cancer and versus Keytruda in first-line. The firm says this is "unprecedented" and paves a path to capture and expand the growing $50B checkpoint inhibitor market. It cites ivonescimab's potential to demonstrate superior efficacy across solid tumors for the Buy rating.
Jefferies
Kelly Shi
Buy
upgrade
$31 -> $44
2025-04-25
Reason
Jefferies
Kelly Shi
Price Target
$31 -> $44
2025-04-25
upgrade
Buy
Reason
Jefferies analyst Kelly Shi raised the firm's price target on Summit Therapeutics to $44 from $31 and keeps a Buy rating on the shares. Ivonescimab gained approval in China for first-line platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer, the analyst tells investors in a research note, citing a posting on the National Medical Products Administration website. The firm remains "optimistic" and sees "skewed upside" for Summit shares on the HARMONi-2 study. In light of the HARMONi-6 topline data and H-2 approval, Jefferies increased its probability of success on the first-line NSCLC global trials of HARMONi-7 and HARMONi-3. Today's China approval news marks Ivonescimab's second win in NSCLC, a much larger indication than the first approval, the firm says.
Cantor Fitzgerald
Eric Schmidt
Buy
Reiterates
n/a
2025-04-23
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
n/a
2025-04-23
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Summit Therapeutics Inc (SMMT.O) is -52.02, compared to its 5-year average forward P/E of -15.15. For a more detailed relative valuation and DCF analysis to assess Summit Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.15
Current PE
-52.02
Overvalued PE
6.04
Undervalued PE
-36.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.01
Current EV/EBITDA
-42.78
Overvalued EV/EBITDA
9.34
Undervalued EV/EBITDA
-31.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
340.45
Current PS
1111.53
Overvalued PS
925.45
Undervalued PS
-244.54

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

SMMT News & Events

Events Timeline

(ET)
2025-06-02
13:32:16
Bristol deal takes out 'key' potential buyer of Summit Therapeutics, says Truist
select
2025-05-30 (ET)
2025-05-30
06:05:48
Summit Therapeutics announces topline results from Phase 3 HARMONi trial
select
2025-04-25 (ET)
2025-04-25
15:51:20
Citi says buy Summit amid 'significant market confusion'
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
06-15Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against Summit Therapeutics Inc. following a significant drop in stock price after the company announced disappointing results from a Phase III clinical trial of its drug ivonescimab.

  • Stock Impact: The announcement on May 30, 2025, led to a 30.5% decline in Summit's stock price, closing at $18.22 per share, as the drug failed to show a statistically significant improvement in overall survival despite some positive trial results.

Preview
7.0
06-12PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Summit Therapeutics Inc. following a significant drop in stock price after the announcement of disappointing Phase III clinical trial results for their drug ivonescimab.

  • Stock Market Impact: After the May 30, 2025 press release detailing that ivonescimab did not show a statistically significant improvement in overall survival compared to chemotherapy alone, Summit's stock plummeted by 30.5%, closing at $18.22 per share.

Preview
4.0
06-12NASDAQ.COM
Why Summit Therapeutics Stock Tanked Today
  • Analyst's Downgrade Impact: Summit Therapeutics' stock fell over 11% after analyst Daina Graybosch from Leerink Partners initiated coverage with an underperform rating and a price target of $12 per share, significantly below its recent closing price.

  • Concerns Over Drug Marketability: The analyst expressed skepticism about the market potential for ivonescimab, a cancer drug licensed from Akeso, citing challenges in gaining market share and higher hurdles for clinical success compared to existing treatments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Summit Therapeutics Inc (SMMT) stock price today?

The current price of SMMT is 19.85 USD — it has decreased -0.5 % in the last trading day.

arrow icon

What is Summit Therapeutics Inc (SMMT)'s business?

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

arrow icon

What is the price predicton of SMMT Stock?

Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 33.50 USD with a low forecast of 12.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Summit Therapeutics Inc (SMMT)'s revenue for the last quarter?

Summit Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Summit Therapeutics Inc (SMMT)'s earnings per share (EPS) for the last quarter?

Summit Therapeutics Inc. EPS for the last quarter amounts to -0.09 USD, increased 50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Summit Therapeutics Inc (SMMT)'s fundamentals?

The market is revising No Change the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.39%.
arrow icon

How many employees does Summit Therapeutics Inc (SMMT). have?

Summit Therapeutics Inc (SMMT) has 159 emplpoyees as of June 18 2025.

arrow icon

What is Summit Therapeutics Inc (SMMT) market cap?

Today SMMT has the market capitalization of 14.74B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free